POPULARITY
Categories
103 episodes with annual meetings
111 episodes with annual meetings
87 episodes with annual meetings
85 episodes with annual meetings
54 episodes with annual meetings
66 episodes with annual meetings
56 episodes with annual meetings
53 episodes with annual meetings
49 episodes with annual meetings
38 episodes with annual meetings
39 episodes with annual meetings
25 episodes with annual meetings
29 episodes with annual meetings
56 episodes with annual meetings
29 episodes with annual meetings
19 episodes with annual meetings
23 episodes with annual meetings
26 episodes with annual meetings
23 episodes with annual meetings
37 episodes with annual meetings
25 episodes with annual meetings
30 episodes with annual meetings
19 episodes with annual meetings
14 episodes with annual meetings
17 episodes with annual meetings
13 episodes with annual meetings
16 episodes with annual meetings
16 episodes with annual meetings
15 episodes with annual meetings
15 episodes with annual meetings
13 episodes with annual meetings
14 episodes with annual meetings
16 episodes with annual meetings
11 episodes with annual meetings
10 episodes with annual meetings
11 episodes with annual meetings
19 episodes with annual meetings
15 episodes with annual meetings
11 episodes with annual meetings
13 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
17 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
14 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
9 episodes with annual meetings
8 episodes with annual meetings
14 episodes with annual meetings
12 episodes with annual meetings
7 episodes with annual meetings
9 episodes with annual meetings
10 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
11 episodes with annual meetings
14 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
9 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
9 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
9 episodes with annual meetings
13 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
14 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
7 episodes with annual meetings
7 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
10 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
3 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
20 episodes with annual meetings
3 episodes with annual meetings
6 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
12 episodes with annual meetings
8 episodes with annual meetings
8 episodes with annual meetings
6 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
4 episodes with annual meetings
5 episodes with annual meetings
7 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
7 episodes with annual meetings
2 episodes with annual meetings
6 episodes with annual meetings
2 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
10 episodes with annual meetings
3 episodes with annual meetings
8 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
9 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
3 episodes with annual meetings
12 episodes with annual meetings
3 episodes with annual meetings
3 episodes with annual meetings
4 episodes with annual meetings
4 episodes with annual meetings
6 episodes with annual meetings
10 episodes with annual meetings
2 episodes with annual meetings
4 episodes with annual meetings
60 episodes with annual meetings
3 episodes with annual meetings
The employment law landscape is evolving rapidly, especially for health care employers. Timothy A. Hilton, Partner, Husch Blackwell LLP, and Gary McLaughlin, Partner, Mitchell Silberberg & Knupp LLP, discuss the areas of greatest concern for health care employers. They cover wage and hour issues, considerations related to remote work, and religious and ADA accommodation issues. Timothy and Gary spoke about this topic at AHLA's 2025 Annual Meeting in San Diego, CA.Watch this episode: https://www.youtube.com/watch?v=T_ltW2fsTWoLearn more about the AHLA 2025 Annual Meeting that took place in San Diego, CA: https://www.americanhealthlaw.org/annualmeeting Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.
Fertility & Sterility on Air is at the European Society of Human Reproduction and Embryology 41st Annual Meeting in Paris, France (Part 1)! In this episode, our hosts Kate Devine, Eve Feinberg, and Micah Hill cover: outcomes from programmed ovulatory frozen embryo transfer cycles vs. modified natural frozen embryo transfer cycles with Philippos Edimiris (0:56), non-invasive preimplantation genetic testing using metabolomics with Sofia Nunes (9:23), optimizing timing of modified natural cycle frozen embryo transfer cycles with Amelie Johansen and Kristine Løssl (17:46), mechanisms and consequences of ovarian aging with Francesca Duncan (27:18), comparing pregnancy loss rates in natural cycle vs. artificial cycle endometrial preparation prior to euploid embryo transfer with Caroline Roelens (38:24), and endometrial health and reproductive outcomes with Shari Mackens(49:44). View Fertility and Sterility at https://www.fertstert.org/
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.” He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.” In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support. https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections. The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs. Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs. In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide). The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems. Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study. “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries. They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment. https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year. The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app. https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care. Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations. The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe. The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market. The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems. Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation. Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options. It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems. “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra. Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes. The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations. ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna. The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape. “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.” https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results… Well maybe that's overplaying it a little. Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better. Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/ XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic. Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana. “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp. He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could. “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp. He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s. “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp. Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes. Bob credits his late wife, Donna, for helping him beat the odds. “She has been key in that I always ate on time.” They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner. “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp. Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps. “I'm not satisfied with the sensors they have today. I just don't think they're accurate.” To many, Bob's survival is extraordinary. To him, it's luck. “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp. And through it all, optimism has been his compass. “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp. He still welds nearly every day. Not because he has to, but because it keeps him going. “As long as I keep doing something like this, I will not be in the nursing home,” said Delp. https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond. Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?: An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.
Abdul and Katelyn discuss the week in public health, which includes: RFK Jr's MAHA Report, and why it fails to deliver meaningful change The leaked report that revealed RFK Jr will tie Tylenol use to autism The firing of CDC Director Susan Monarez, and the mass resignations that followed RFK Jr's Senate testimony, which included a grilling from top Republicans Then Abdul talks to Natalie Foster, president of the Economic Security Project, about the power of guaranteed income in health outcomes. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25. Incogni: Take your personal data back with Incogni! Use code DISSECTED at the link below and get 60% off an annual plan: https://incogni.com/dissected
Welcome to 'AI Lawyer Talking Tech,' your weekly deep dive into the legal world's embrace of artificial intelligence. Today, we're dissecting the profound shifts occurring across the legal sector, from the exciting advancements in agentic AI streamlining firm operations and transforming contract review to the critical concerns surrounding data security in the cloud and AI-driven data scraping. We'll also explore the emerging legal frameworks for automated decision-making and digital identity rights, alongside the evolving strategies law firms must adopt for AI visibility and trust in their online presence. Join us as we unpack how AI is reshaping legal practice, demanding both innovation and heightened responsibility from legal professionals.Law Firms And The Cloud: Is Your Data As Safe As You Think?2025-09-09 | Above The Law[Guest post] Digital replicas of the dead: a growing trend, a missing legal framework2025-09-09 | The IPKatACC Announces Its 2025 Annual Meeting in Philadelphia2025-09-09 | Legal ReaderWhy legal professionals need purpose-built agentic AI2025-09-09 | Thomson ReutersRevolutionizing Legal Workflows with AllRize's AI Solution2025-09-09 | InvestorsHangout.comContract Drafting & Review in the Age of GenAI2025-09-09 | AIJourn.comFour Legal Tech Companies Make the Forbes Cloud 100 and Two Others are Rising Stars2025-09-09 | LawSitesHow Law Firms Can Future-Proof Their Content in the Age of AI Search2025-09-09 | Articles, Tips and Tech for Law Firms and LawyersOn LawNext: From Law Student Startup Founder to Global CEO: Daniel Lewis's Legal Tech Journey2025-09-09 | LawSitesPixalate Research Finds 253 EU & UK-Registered Mobile Apps Likely Violating GDPR-K & UK Children's Code2025-09-09 | ExchangeWireSome Thoughts on AI and Conflict Management2025-09-09 | SlawWeb Defences Against A Rising Tide Of AI Data Scraping2025-09-09 | CyberSecurityIntelligence.comBurford Capital Partners with Kindleworth to Transform Legal Services2025-09-09 | InvestorsHangout.comWhy Sensitive Data Demands A Private Cloud Approach To AI2025-09-09 | Forbes.comWhy Digital Currency and Web 3.0 Lawyers Are Becoming Essential in India2025-09-09 | WriteUpCafe.comExclusive: AnthroTek raises £950K seed round in the UK's first AI-only legal deal2025-09-09 | Tech Funding NewsHow Law Firms Can Use AI Tools To Streamline Client Intake2025-09-09 | Young UpstartsHow Law Firms Can Build Legal Authority on X and LinkedIn for AI Visibility and Trust2025-09-09 | Legaltech on MediumMiddlemen Asia: Bridging Legal Access with Smart AI and Advocacy2025-09-09 | Legaltech on MediumLaw Punx: Law Firms Don't Know Why They're Buying AI2025-09-09 | Artificial LawyerEyes on Michigan: What Businesses Need to Know About Pending Consumer Privacy and Identity Theft Legislation2025-09-09 | Fisher & Phillips LLPHolland & Knight Health Dose: September 9, 20252025-09-09 | Holland & KnightAutomated decision-making among new Law Commission projects2025-09-08 | Legal FuturesNew leaders join the International Institute2025-09-08 | UCLA International Institue
Tonight's show comes to you from the 2025 NWA Annual Meeting in Huntsville at the Von Braun Civic Center. Janice Bunting is the Executive Director of the NWA stops by first to talk to the panel. She's pulled off an amazing event this year under trying circumstances. Throughout the evening, other notable leaders in the weather industry will also stop by to chat with our panel about this year's meeting — sharing their insights, highlights, and what it all means for the future of meteorology. Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Bob Baron and other sponsors of the Annual Meeting (04:20) Roadmap for the NWA going forward (07:30) Louis Uccellini talks about the initial NWA in the early days of the organization (27:00) Force multiplier nature of social media (45:00) Panel discussion with industry's leading digital meteorologists (59:00) Hand-drawn animations for the conference (01:06:00) Goals for the upcoming year in NWA (01:10:00) Cooperation with AMS (01:14:00) Nate Johnson discusses student support within the organization (01:26:00) Nate's IWT (Integrated Warning Team) takeaways (01:30:30) Dr. Chuck Graves stops by to chat with the panel (01:48:00) The Astronomy Outlook with Tony Rice (01:54:55) This Week in Tornado History With Jen (01:57:05) E-Mail Segment (No segment this week - STAY TUNED!) and more! Web Sites from Episode 1025: Alabama Weather Network Picks of the Week: James Aydelott - James Aydelott photographed in back of patrol car Jen Narramore - Foghorn Rick Smith - Out Troy Kimmel - Foghorn Kim Klockow-McClain - Foghorn John Gordon - A New Spin On Waterspout Forecasting (Published August 2014) John Gordon - A Waterspout Forecasting Technique Bill Murray - Foghorn James Spann - FCC Proposes Modernization of the Nation's Alerting Systems The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Since we are at the very start of the holiday season, at least for businesses (and yes it is the start of the holiday season for business), company leaders both big and small have to start planning. Whether it's holiday parties, sales kickoffs, or, of course, annual meetings, the planning has to begin now, and it's worth planning them the right way. In the case of annual meetings, the importance is apparent. Most companies only get all the employees together once a year, and typically that is at the annual meeting, so every piece of information and every learning activity that is done is vital with little room for filler. Despite this, annual meetings can be prime suspects for employee disengagement. Forcing a group of team members to learn and discuss necessary parts of business right after most have had a break and are just starting to get back into the swing of things is naturally going to lead to tuning out. It doesn't have to be that way though. Stick around for five excellent tips to ensure every employee at the annual get together is focused and learning every step of the way. Show Notes: 5 Tips to Solve Team Disengagement in Annual Meetings(https://www.leadersinstitute.com/5-tips-to-solving-team-disengagement-with-team-building-activities/)
Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.” Our full disclosures are available in the transcript of this episode. And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%. And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting. So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course. And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera
New Zealand First wants to make KiwiSaver compulsory, and increase contributions to eight, then 10 percent. Political reporter Russell Palmer has more.
The Petersfield Society, dedicated to preserving the character of the town and villages, has its 79th Annual Meeting on Thursday 18 September at 7pm at the United Reform Church on College Street. It’s presenting its annual Owl award to charity in town (revealed on the night), hearing from key note speaker Malcom Farrow on Flags (Petersfield has one for instance) and is looking for new ideas they can help with. Clive Cook, a Trustee, talking to Mike Waddington and Marcus Fairweather, tells us about what the Society does, the publications it has produced - with another due this year - and ideas and projects they can work with the community on. More at :HOME - Petersfield SocietySee omnystudio.com/listener for privacy information.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Kenneth Waller, Chief Executive Officer of Norwalk Community Health Center. He shares how the organization is scaling services, leveraging data and AI, and staying mission-focused while navigating funding challenges and industry uncertainty.
Tonight's Guest WeatherBrain is a meteorologist, climatologist, instructor, and now author. She has a brand new book just released titled "Wilder Weather: What Laura Ingalls Wilder Teaches Us About Weather, Climate, And Protecting What We Cherish". In her book, she digs deep into Wilder's depictions of weather events and helps readers connect past weather to present weather. She's worked at NOAA for over 23 years. Dr. Barbara Boustead, it's great to have you on the show! Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Introduction to Laura Ingalls Wilder and he r background (13:00) Entire Little House on the Prairie series (14:45) Analyzing 1880s weather records in Dakota Territory (19:00) Laurapalooza Conference (21:45) Weather in Wilder's other works (24:15) Further examples of Wilder's writings about weather events (34:30) Today's different climate from the era of authors like Charles Dickens (44:00) Climate is the past, present, and future (50:00) Encouraging teachers to use "Wilder Weather" in lesson plans (58:30) Weather folklore (01:00:00) Where can you order "Wilder Weather"? (01:10:00) Tips for aspiring authors (01:24:00) The Astronomy Outlook with Tony Rice (01:11:20) This Week in Tornado History With Jen (01:12:50) E-Mail Segment (01:14:05) and more! Web Sites from Episode 1024: Alabama Weather Network Wilder Weather "Wilder Weather: What Laura Ingalls Wilder Teaches Us About the Weather, Climate, and Protecting What We Cherish" by Dr. Barbara Boustead Picks of the Week: Dr. Barbara Boustead - "The Beautiful Snow" by Cindy Wilson James Aydelott - Meteogram for Camargo, OK/90+mph winds Jen Narramore - Merry violent phenomenon in Morbihan on 2 September Rick Smith - Here's one of the first photos of a tornado ever Troy Kimmel - Out Kim Klockow-McClain - NWA 50th Annual Meeting in Huntsville, AL John Gordon - ATR-72 nearly flipped over from 99 mph winds in Corsica John Gordon - Reagan's near-death experience in 1983 Bill Murray - "The Weather Gods Curse the Gettysburg Campaign" by Jon M. Nese and Jeffrey Harding James Spann - Sandblasted to Death: 1935 Labor Day Hurricane The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Illinois Rep. John Cabello explains how Republicans in a super minority can still fight back, rally citizens & hold the majority accountable. Special Guest: John Cabello.
Show Highlights: Field to Market's unique positioning in the ag value chain. [04:51] Why equal voices matter in a cross-sector coalition. [06:26] What are Field to Market's core functions and tools? [07:57] The value of real ag sector experience for coalition leadership. [10:42] Sustainability insights by agribusinesses from Field to Market's Annual Meeting. [15:00] M&A lessons from harnessing diversity in coalitions. [27:41] The role of collaborative data in the Triscuits supply chain. [31:24] How U.S. Cotton Trust Protocol assesses sustainability. [36:26] Discover what's next for Field to Market—and participate. [40:45] To learn more about Field to Market, go to https://fieldtomarket.org/. To check out Field to Market's membership, visit https://fieldtomarket.org/our-members/ To learn how Field to Market defines sustainability, visit https://fieldtomarket.org/defining-sustainability/ To join the Sustainable Agriculture Summit, visit https://fieldtomarket.org/contact-us/events/sustag-summit/. Find Carrie on LinkedIn at https://www.linkedin.com/in/carrievollmersanders/. If you are interested in connecting with Joe, go to LinkedIn: https://www.linkedin.com/in/joemosher/, or schedule a call at www.moshercg.com.
"THANK YOU," from the entire team at Biblical Higher Ed Talk. A special message from Phillip Dearborn.A sneak peek into Season 5Speakers for ABHE 79th ANNUAL MEETING: A Time to Lead -- February 11-13, 2026. We are approaching 10,000 downloadsBiblical Higher Ed Talk is to be a part of The Higher Ed Marketer Podcast Network. To hear this interview and many more like it, subscribe on Apple Podcasts, Spotify, or our website, or search for Biblical Higher Ed Talk in your favorite podcast player.Hosted by Ausha. See ausha.co/privacy-policy for more information.
Join host David Werho (UC San Diego/Rady Children's) and guests Carly Scahill (Colorado Children's), Lillian Su (Phoenix Children's), and Yaeji Kim (IG: @chd_doodles) as they discuss the upcoming 2025 PCICS Annual Meeting in Austin, TX, co-hosted by The Texas Center for Pediatric and Congenital Heart Disease at Dell Children's Hospital. We speak about many of the plenary sessions, breakouts, social events, and things to do in Austin! Host/Editor/Producer: David Werho Platinum Sponsor: Prolacta BioScience
WeatherBrains Episode 1023A is a preview of the upcoming 2025 NWA Annual Meeting in Huntsville, AL. The meeting is only two weeks away from the date of recording (August 25th, 2025). Show veteran Kevin Laws joins us to dive into the upcoming NWA Annual Meeting in Huntsville. He currently serves as the SOO (Science and Operations Officer) of the Birmingham, AL NWS office. Kevin, it's great to see you again. David from the Texas Storm Chasers also drops in to chat with the panel about what to expect at the meeting. Our email officer Jen is continuing to handle the incoming messages from our listeners. Reach us here: email@weatherbrains.com. Tropics remain quiet (02:45) Starting the dialogue of a changing business model (07:55) Baby steps toward progress in the field starting over 15 years ago (11:00) Gatekeeping and resentment among various sectors in meteorology (12:00) Objectives of the upcoming Annual Meeting (23:00) The outdated concept of TV market boundaries (36:00) NWA registration procedures (44:00) How do we define expertise in 2025? (48:30) What will the broadcast transition look like moving forward? (50:45) The Astronomy Outlook with Tony Rice (No segment for this episode) This Week in Tornado History With Jen (No segment for this episode) E-Mail Segment (No segment for this episode) and more! Web Sites from Episode 1023A: 2025 NWA Annual Meeting September 6-10th, 2025 Huntsville AL Alabama Weather Network Alabama Weather Network on Facebook Picks of the Week: James Aydelott - Cool noon temperatures in Oklahoma Jen Narramore - Out Rick Smith - The OCS/Mesonet Ticker Troy Kimmel - Foghorn Kim Klockow-McClain - Foghorn John Gordon - Out Bill Murray - Out James Spann - Foghorn The WeatherBrains crew includes your host, James Spann, plus other notable geeks like Troy Kimmel, Bill Murray, Rick Smith, James Aydelott, Jen Narramore, John Gordon, and Dr. Kim Klockow-McClain. They bring together a wealth of weather knowledge and experience for another fascinating podcast about weather.
Our preview of the upcoming AACPDM Conference in New Orleans USA.We look ahead at The American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Conference - the 79th Annual Meeting!“Celebrating Resilience” October 15-18, 2025, to be held in New Orleans, LA. We catch up with AACPDM First Vice President Dr Theresa Sukal-Moulton and Scientific Program Committee Co-Chair Dr Paige Church.You can still register at the link below!https://www.aacpdm.org/events/2025
A Conversation in Veterinary Pathology - The A.C.V.P. Podcast
In this episode, we chat with Dr. Olivia Patania and Dr. Lauren Stranahan of the ACVP Student Engagement Committee. They discuss veterinary student happenings at the 2024 ACVP/ASVCP annual meeting and upcoming exciting events for the 2025 Annual Meeting in New Orleans, LA. Have you thought about volunteering for ACVP? We hear how they started and why it's important. The Doctors also discuss the best time in your career to get interested in veterinary pathology - spoiler alert - it's anytime! So grab a comfy chair and get ready for a conversation with Dr. Olivia Patania and Dr. Lauren Stanahan. ___ Links Veterinary Student Engagement - https://acvp.org/training/veterinary-student-engagement/ 2025 ACVP Pathletes Registration 2025 Annual Meeting in NOLA Student Externship Scholarships Season 02, Episode 04 - A Conversation with Dr. Mara Varvil Season 02, Episode 05 - A Conversation with Dr. Keith Nelson of the Student Externship Scholarship Committee ACVP Errors in Publications Portal ACVP Training Program Accreditation ___ ACVP Student Engagement's Social Media Facebook: ACVP Veterinary Student Engagement Instagram: acvp_student_engagement ____ ACVP Social Media Facebook - ACVP Meetings and Topics Instagram - americancollegevetpath X (Twitter) - @ACVP LinkedIn - AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS ____ Acronyms STP = Society of Toxicologic Pathology DTF = Davis Thompson Foundation ____ Music: Guestlist by Podington Bear, licensed under an Attribution-NonCommercial 3.0 International License. The contents of this audio do not necessarily reflect the opinions of the American College of Veterinary Pathologists (ACVP) or the participants' affiliations. Spoken audio content and associated photos are the property of the American College of Veterinary Pathologists, 2025.
One of North Carolina's newest legislators tackles property tax reform with confidence and conviction. North Carolina Representative Brian Echevarria spoke with ALEC Director of Policy Advancement and Media Relations Lars Dalseide on ALEC TV about turning a family challenge into a political calling by championing property tax reform. Special Guest: Brian Echevarria.
ALEC Board Member Jim Dotson shares how Arkansas climbed into the top 10 in economic competitiveness and why it won't stop there. Special Guest: Jim Dotson.
As we celebrate the 6th Anniversary of NSTA: The Bus Stop - Executive Director Curt Macysyn welcomes back Daoud Chaaya, Vice President of Sales, Aftermarket, and Marketing at Thomas Built Buses (TBB). As the school year kicks off across the country, Daoud shares his insight in student transportation, as we as his own background, updates from Thomas Built Buses, and his observations from NSTA's Annual Meeting and Convention in Boston. The duo discuss Thomas Built Bus's sponsorship of the Awards and Installation Dinner, the current industry landscape, key challenges such as tariffs, and notable product updates from Thomas Built Bus. Daoud also shares personal reflections and directs listeners to resources for learning more about the company. Become a podcast subscriber and don't miss an episode of NSTA: The Bus Stop - NSTA Vendor Partners should reach out to us to take advantage of our comprehensive advertising package that reaches your target audience - student transportation professionals! Check out this episode's advertisement from First Light Safety Products and see if podcast advertising is right for you.Support the show
We're jumping into your feed midweek to share an interview with Adam from this past June by our friends at the Radio Davos podcast. We'll be back with a new episode on Friday. Radio Davos is a weekly podcast from the World Economic Forum that looks at the biggest challenges facing the world, and how they might be tackled. Find it wherever you get podcasts or at wef.ch/podcasts. Video-podcasts are posted at https://www.youtube.com/@wef/podcasts. This episode of Radio Davos, an interview with Adam Tooze, was recorded at the World Economic Forum's Annual Meeting of the New Champions in Tianjin, China on June 25, 2025. Historian and podcaster Adam Tooze says we are at a turning point in history - as the Trump administration upends decades of assumptions on geopolitics, trade and the economy. Coinciding with the dawn of artificial intelligence, the rise of China, and demographic shifts are adding to transformative changes for us all. CNBC anchor Chery Kang joins us in the studio at AMNC25 to co-host the episode. This is a video-podcast, watch it on our YouTube channel: http://wef.ch/3GFeAvl Related podcasts: Halfway through 2025, reasons to be optimistic in a turbulent year Three experts on how to understand the USA Tariffs, globalization, and democracy, with Harvard economist Dani Rodrik Check out all World Economic Forum podcasts on wef.ch/podcasts: YouTube: https://www.youtube.com/@wef Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Social handles: LinkedIn https://www.linkedin.com/in/robin-pomeroy/ https://www.linkedin.com/company/world-economic-forum/ https://www.linkedin.com/company/cnbc/ https://www.linkedin.com/in/chery-kang-ab5430175/https://www.linkedin.com/showcase/cnbc-international/ X @RobinPomeroyEd @adam_tooze @wef @cherykang@cnbci @OnesandToozePod @ForeignPolicy Learn more about your ad choices. Visit megaphone.fm/adchoices
On this episode of Soundbites of the Annual Meeting, we talked to Kimberly Haugstad, CEO of RareRising and a longtime rare disease advocate who is also the parent of a child with severe hemophilia. In her conversation with ASGCT's Communications Committee Chair, Lynnea Olivarez, Kimberly discusses: why patients, as the "lived experience experts" are so important to rare disease communications advice for scientists who would like to engage more directly with patient communities what's giving her hope right now Listen and subscribe to the ASGCT Podcast Network so you don't miss any episodes!Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
In this special episode of the IPhO Podcast, Waleed Elsweesy, Current National Student Officer for Marketing & Partnerships, sits down with Melissa Rodenbach, IPhO Vice President, Marketing and Communications; and Daniel Ghattas, Former National Student Officer for Marketing & Partnerships and current first-year Fellow at Pfizer in U.S. & Global Medical Affairs, Hematology/Oncology; to talk all things IPhO Annual Meeting! They answer some of the most common student questions: Why should I attend as a P1, P2, or P3? What makes the meeting valuable for P4s preparing for fellowship recruitment? How can I make the most of networking and content sessions? What deadlines do I need to know about now? Whether you're just starting your journey exploring the industry or you're preparing to take your biggest step yet, this episode gives you insider advice on how to navigate the meeting, connect with industry leaders, and leave with a plan for success.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Peter Banko, President and Chief Executive Officer, Baystate Health. Peter shares insights on improving organizational agility through streamlined decision-making, addressing access challenges with a coordinated care model, and balancing flexible work with community and cultural revitalization.
A Conversation in Veterinary Pathology - The A.C.V.P. Podcast
Today's guest is Dr. Abby Armwood, an Assistant Professor in the Department of Population Health and Pathobiology at North Carolina State University, College of Veterinary Medicine. Dr. Armwood sat down with us at the 2024 ACVP/ASVCP Annual Meeting in Seattle, WA, to tell us more about the ACVP Student Engagement Committee (SEC) and their commitment to creating fun and educational events. Hear more about Patheletes, kicking off at the 2025 Annual Meeting in New Orleans, LA, and the veterinary student mentoring program. Dr. Armwood also discusses the Pathology Training Committee and its role in enhancing the quality of pathology training programs. And, we hear about her journey in pathology–from an interest in becoming an aquatic veterinarian to expertise in all things aquatic pathology! Grab a snack and join us for a conversation with Dr. Abby Armwood. If you want to connect with the ACVP SEC, you can find them: Facebook - ACVP Veterinary Student Engagement Committee ___ More Information on: 2025 ACVP Annual Meeting in NOLA Maintenance of Certification More Information on the ACVP Training Program Accreditation AQUAVET(R) - Cornell University College of Veterinary Medicine ACVP Errors in Publications Portal ___ ACVP Social Media Facebook - ACVP Meetings and Topics Instagram - americancollegevetpath X (Twitter) - @ACVP LinkedIn - AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS ____ Thank you to Dr. Andrea Kerr, of the MCC Podcast Subcommittee, for editing this episode. Music: Guestlist by Podington Bear, licensed under an Attribution-NonCommercial 3.0 International License. The contents of this audio do not necessarily reflect the opinions of the American College of Veterinary Pathologists (ACVP) or the participants' affiliations. Spoken audio content and associated photos are the property of the American College of Veterinary Pathologists, 2025.
At the 52nd ALEC Annual Meeting, Michigan Speaker Matt Hall described his priorities as rooted in the belief that economic growth and public safety go hand in hand. By focusing on a business climate that rewards investment, infrastructure spending that delivers results, and policies that respect the rule of law, he believes Michigan can compete with the strongest states in the nation while protecting the communities that call it home. Special Guest: Matt Hall.
- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO
- Treatment Updates from ASCO 2025 on Lung Cancer - Supportive Care Issues - Treatment Updates from ASCO 2025 on Colorectal Cancer - Quality-of-Life Concerns - Update on Pancreas Cancer - Supportive Care Concerns - Update on Lymphoma - Communicating with Your Health Care Team - Updates on Leukemia from ASCO - Managing Treatment Side Effects - Updates on Melanoma from ASCO - Wrap-Up of Part II of Highlights from ASCO
Meetings Today's Tyler Davidson caught up with new San Diego Tourism Authority President & CEO Daniel Kuperschmid at ASAE's Annual Meeting to find out what the new DMO leader's objectives are, how his 30-year career in hotels informs his new position, major meetings-related developments in what may be the hottest destination in the U.S., and some of the undiscovered gems of this SoCal standout.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Stephanie Everett, Administrator of Mountrail Bethel Home and Chief Executive Officer of Mountrail County Medical Center. She shares her journey from foundation director to CEO, highlights a $53 million expansion project, and discusses the importance of listening to staff, addressing rural staffing challenges, and embracing technology to deliver the best possible patient care.
City Quick Connect Podcast from the Municipal Association of South Carolina
The Association's podcast hosted drop-in interviews throughout the 2025 Annual Meeting for officials to share the positive impacts their municipality has achieved for residents. Hear from Fountain Inn Mayor GP McLeer, Georgetown Councilmember Tamika Williams-Obeng, Laurens Councilmember Calvin Whitmire and Beaufort Deputy City Manager JJ Sauve.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Dr. Cliff Megerian, Chief Executive Officer, University Hospitals. Dr. Megerian shares how UH is leading with a culture of compassion, advancing patient-centered hospitality, addressing financial pressures with strategic efficiency, and cultivating a resilient workforce through retention and internal career development.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Stephanie Martinez, Executive Director and Associate Chief Nursing Officer for the Care Continuum, Boston Medical Center Health System. She shares how multidisciplinary efforts to reduce length of stay improved care systemwide, and discusses the importance of supporting an evolving nursing workforce through retention strategies and shared decision-making.
Montana State Representative Kerri Seekins-Crowe may represent just over 10,000 constituents in Yellowstone County, but she carries the concerns of Montana's working families with her wherever she goes. At ALEC's 52nd Annual Meeting in Indianapolis, the ALEC State Chair reflected on her path into public service, her recent legislative priorities, and what she hopes to take home from the conference. Special Guest: Kerri Seekins-Crowe.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Kimberly Probus, Chief Nursing Officer, El Centro Regional Medical Center. She shares insights on reviving a struggling hospital, building interdisciplinary teams, and addressing workforce challenges post-COVID through innovative recruitment and retention strategies tailored to her community.
On this episode of Soundbites of the Annual Meeting, we talked to Mimi Lee, MD, PhD, a physician-scientist and program manager at the Advanced Research Projects Agency for Health (ARPA-H). In her conversation with ASGCT's Communications Committee Chair, Lynnea Olivarez, Dr. Lee discusses: ARPA-H's unique approach to funding and structuring CGT development breaking down silos to improve health outcomes for all the role that CGT will play in prevention, rather than just treatment, of diseases Listen and subscribe to the ASGCT Podcast Network so you don't miss any episodes!Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Matt Morton, Executive Director and Chief Information Security Officer, University of Chicago. He shares how his team is securing AI tools like Phoenix AI to support clinical research, discusses the cybersecurity staffing and resource challenges faced by academic medical centers, and emphasizes the importance of adaptability in leading through rapid technological change.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Trevor Martin, Chief Information Security Officer, UW Health. He shares how his team is navigating AI implementation through staff literacy initiatives, advancing virtual care to improve access, and fostering a culture of flexibility and human-centered leadership.
Elder Samuel Bryant was the guest minister during out 2025 Annual Meeting. This first message was delivered on Friday evening, 6/27/25, and is based on Hebrews 4:14-16.
Elder Samuel Bryant was the guest minister for our 2025 Annual Meeting. In the second message of the weekend (Saturday morning, 6/28/25), Brother Bryant exposits Ephesians 6:10ff.
Elder Samuel Bryant was the guest minister for our 2025 Annual Meeting. In the Saturday afternoon service (6/28/25), Br Sam exposits Ephesians 1:1-11.
In the Sunday morning (6/29/25) service of our 2025 Annual Meeting, visiting preacher Elder Samuel Bryant considers the profoundly simple and simply profound 23rd Psalm.
Speaker Daniel Hawkins talks budget discipline, building camaraderie, and leadership at the ALEC Annual Meeting in Indianapolis. Special Guest: Daniel Hawkins.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Michele Szkolnicki, Senior Vice President and Chief Nursing Officer, Penn State Health Milton S. Hershey Medical Center. Michelle shares how her team has restored staffing levels, prioritized nurse well-being, and creatively restructured workforce roles to meet post-COVID challenges and strengthen the future of bedside nursing.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Kenneth Waller, Chief Executive Officer of Norwalk Community Health Center. He shares how the organization is scaling services, leveraging data and AI, and staying mission-focused while navigating funding challenges and industry uncertainty.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Cathy Stankiewicz, Chief Nursing Officer, AdventHealth Central Florida Division. She shares how her team is strengthening the nursing workforce through professional governance, early career pipeline development, and flexible leadership in the face of workforce shortages and population growth.
This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Pete November, Chief Executive Officer of Ochsner Health. He shares insights on elevating the role of nurses, tackling workforce development, and transforming care through innovation, education, and a deeply human-centered leadership approach.
This year's Annual Meeting featured a special event focused on spiritual healing. Join cohosts Tony Lobl and David Brown for this interactive Sentinel Watch, complete with questions from a participating audience, several of them on how to pray about current world events.
© 2020-2025 Ivy Podcast Discovery LLC
